Abstract:To review key trials of monotherapy and combination therapy of α1-adrenergic receptor antagonists (α1-ARAs), 5α-reductase inhibitors (5αRIs) and anti-muscarinic agents in the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976–2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, α1-adrenergic receptor antagonists, 5α-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil. Data from the Medical Therapy of Prostatic Symptoms (MTOPS) study indicated a role for long-term use of α1-ARAs and 5αRIs in combination. In the MTOPS study, combination therapy with the α1-ARA doxazosin and the 5αRI finasteride was significantly more effective than either component alone in reducing symptoms (P=0.006 vs doxazosin monotherapy; P<0.001 vs finasteride monotherapy) and in lowering the rate of clinical progression (P<0.001 vs either monotherapy). These findings were confirmed by the 2-year preliminary results of the Combination of Avodart and Tamsulosin study. In this study, combination therapy of the α1-ARA tamsulosin and the 5αRI dutasteride resulted in a significantly greater decrease in International Prostate Symptom Score (IPSS) when compared with either monotherapy. Several recent trials have studied the efficacy of combining α1-ARAs and anti-muscarinic agents in the treatment of BPH. These studies have found this combination to result in statistically significant benefits in quality of life scores, patient satisfaction, urinary frequency, storage symptoms and IPSS scores. Studies have not shown an increased risk of urinary retention associated with the use of anti-muscarinics in a highly select cohort of men with BPH. The available data suggest that combination therapy can be beneficial in the treatment of BPH and associated LUTS. The greatest efficacy for the α1-ARA and 5αRI combination was shown in patients with larger prostate size and more severe symptoms. The combination of α1-ARAs and 5αRIs appears to prevent disease progression in these patients. The combination of α1-ARAs with anti-muscarinic agents is useful for relieving symptoms of bladder outlet obstruction and detrusor overactivity. Theoretic concerns regarding the risk of acute urinary retention have been refuted in several recent clinical trials; however, it must be noted that the patients in these trials were a highly select cohort of men. Men with overactive bladder and BPH who are not receiving adequate alleviation of symptoms from the first-line α1-ARAs may benefit from the addition of an anti-muscarinic agent.

[Treatments of erectile dysfunction combined with lower urinary tract symptoms associated with benign prostatic hyperplasis].

Personalized Therapeutics of Α1-Blockers In patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia

Personalized Therapeutics of &Amp;alpha;1-Blockers In&nbsp;patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia

Evolving Role of Silodosin for the Treatment of Urological Disorders – A Narrative Review

Study of phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or in combination for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.

Efficacy and Safety of Combined Therapy with Terazosin and Tolteradine for Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia: a Prospective Study

A Systematic Review and Meta-Analysis of the Efficacy and Safety of Tamsulosin Plus Tadalafil Compared With Tamsulosin Alone in Treating Males With Lower Urinary Tract Symptoms Secondary to Benign Prostrate Hyperplasia

Systematic Review and Meta-Analysis on Phosphodiesterase 5 Inhibitors and Α-Adrenoceptor Antagonists Used Alone or Combined for Treatment of LUTS Due to BPH

The risk factors of erectile dysfunction for the aged patients with BPH under different treatments

An Open, Comparative, Multicentre Clinical Study of Combined Oral Therapy with Sildenafil and Doxazosin GITS for Treating Chinese Patients with Erectile Dysfunction and Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.

Comparative Effectiveness of Oral Drug Therapies for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: a Systematic Review and Network Meta-Analysis.

Defining the Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors with Tamsulosin for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia with or without Erectile Dysfunction: A Network Meta-Analysis

The role of combination medical therapy in benign prostatic hyperplasia

Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects

Current Concepts in the Treatment of Genitourinary Tract Disorders in the Older Individual

Tamsulosin and Dutasteride Combination Therapy for Asian Men With Moderate-to-Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Systematic Review of Clinical Considerations That Influence the Prescription

The efficacy of combination therapy of tamsulosin and Qianlie Beixi capsule in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia

Phosphodiesterase-5 Inhibitors for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: a Systematic Review and Meta-Analysis.

Pharmacological Approaches in Managing Symptomatic Relief of Benign Prostatic Hyperplasia: A Comprehensive Review

Combination Therapy with Curcumin Plus Tamsulosin and Finasteride in the Treatment of Men with Benign Prostatic Hyperplasia: a Single Center, Randomized Control Study

A Randomized Placebo-Controlled Study: Phellodendron Bawei Tablets Combined with Standard Management Can Improve Storage Symptoms, Sleep Quality, and Medication Compliance in Patients with Benign Prostatic Hyperplasia Compared to Placebo with Standard Management.